← back to search

Weili Zhao

Shenzhen Institutes of Advanced Technology · CN
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and Immune Cell Function and Interaction.
h-index
29
citations
8,967
works
211
NIH funding
primary concept
Medicine
email

Recent publications

Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study
Cancer Communications 2025cited by 10position: lastdoi
Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology
Cell Reports Medicine 2025cited by 6position: lastdoi
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024)
Blood Science 2025cited by 2position: middledoi
Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study
EBioMedicine 2025cited by 1position: lastdoi
752 | SAFETY AND EFFICACY OF BRENTUXIMAB VEDOTIN IN CHINESE ADULTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMA: A SUBGROUP ANALYSIS OF BRAVE STUDY
Hematological Oncology 2025cited by 0position: lastdoi
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
Journal of Clinical Oncology 2024cited by 26position: middledoi
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Journal for ImmunoTherapy of Cancer 2024cited by 6position: middledoi
Impact of Vitamin E Supplementation on High‐Density Lipoprotein in Patients With Haptoglobin Genotype–Stratified Diabetes: A Systematic Review of Randomized Controlled Trials
Journal of Diabetes Research 2024cited by 3position: middledoi
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma
Chinese Medical Journal 2024cited by 3position: middledoi
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
The Innovation 2023cited by 10position: lastdoi
Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T‐cell lymphoma: an interim analysis from a prospective, observational, real‐world study
Hematological Oncology 2023cited by 0position: lastdoi
Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy
Chinese Medical Journal 2022cited by 19position: middledoi
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
Blood Advances 2021cited by 47position: middledoi
Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
Cancer Communications 2021cited by 34position: lastdoi
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
Frontiers in Oncology 2021cited by 21position: middledoi
Haptoglobin genotypes and risk of vascular complications in a northern Chinese Han population with type 2 diabetes mellitus
International Journal of Diabetes in Developing Countries 2021cited by 0position: middledoi
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Cancer Cell 2020cited by 234position: lastdoi
Advances in targeted therapy for malignant lymphoma
Signal Transduction and Targeted Therapy 2020cited by 131position: lastdoi
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study.
Journal of Clinical Oncology 2020cited by 6position: middledoi
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
The Lancet Haematology 2019cited by 49position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Ou Bai · University of San Francisco4 papers (2020–2025)Yu Hu · Wuhan Union Hospital3 papers (2021–2024)Ting Niu · Changhai Hospital3 papers (2022–2025)Hongmei Yi · Shanghai Jiao Tong University3 papers (2021–2025)Depei Wu · Soochow University3 papers (2021–2024)Wenbin Qian · Soochow University3 papers (2021–2024)Dehui Zou · Tianjin University of Technology3 papers (2020–2024)Guiyun Cui · Union Hospital2 papers (2023–2025)Jianxiang Wang · Zhejiang University2 papers (2022–2024)Li Wang · Kunming University of Science and Technology2 papers (2020–2021)Rong Li · Nanjing Agricultural University2 papers (2021–2024)Xi Zhang · Chengdu Women's and Children's Central Hospital2 papers (2021–2022)Yuhua Li · Fudan University2 papers (2022–2024)Panpan Zheng · Hebei Medical University2 papers (2021–2024)Kailin Xu · Vanderbilt University Medical Center2 papers (2022–2024)Bing Xiang · Guangxi Medical University2 papers (2020–2021)Guohui Cui · Union Hospital2 papers (2021–2025)Ke Shi · Yancheng Second People's Hospital2 papers (2023–2025)Haiyi Guo · Kaiser Permanente2 papers (2020–2021)Ziwen Tan · Jiangxi University of Finance and Economics2 papers (2020–2021)